The Non-Small Cell Lung Cancer (NSCLC) Drug Development Summit is the definitive industry-led forum for drug development in the largest solid tumor indication. This is a strategic conference designed to bring drug development teams together to address critical challenges surrounding therapeutic potency, tumor resistance and relapse and expanding the clinical utility of targeted and immuno-therapies, either in combination or monotherapies.
Arriving at a critical point for the NSCLC drug development field, as checkpoint inhibitors are on the brink of entering the perioperative setting and the approval of novel bispecifics with dual oncogenic targeting, this forum will enable you to see a full picture of the clinical trial landscape and identify what MoAs and targets future biopharma investment will be put towards.
Network with 100+ executive biopharma leaders over 3-days of comprehensive insights to uncover the latest industry knowledge on the molecular heterogeneity of lung cancer, the implications for therapeutic design when considering acquired resistance and optimal application of new drugs in the clinic.
Join global innovators to:
Leverage the knowledge gained from the current EGFR-TKI successes to implement it into strategies for improvement, best application strategies and potential combination partners with AstraZeneca, Puma Biotechnology, Cullinan Oncology and Takeda
Unravel the potentials of targeting currently untreatable acquired resistances through small molecules and biologics to develop novel agents against mutations with AbbVie, Merus, Black Diamond, AOM Biosciences and Mirati Therapeutics.
Dive into the exciting advancements in the NSCLC rare mutations space, with the novel therapies in targeting BRAF, NGR1 fusions and HER2 with Kinnate Biopharmaceuticals, Elevar Therapeutics and Boeringer Ingelheim.
Harness the power of the immune system to treat NSCLC by delving into the current best, novel targets and combination strategies to improve patent outlook with Merck & Co, Immutep, BerGenBio and Bristol-Myers Squibb.
Advance the efficacy of companion diagnostics and look to the future of early disease detection, application and differences in patient populations and how combination therapy can best be exploited to beat this drastically unmet clinical need with UAMS, Takeda, Novartis, BloodPAC and Amgen.
The Non-Small Cell Lung Cancer Drug Development Summit features a deep-dive workshop which explores utilizing EGFR-targeting in solid tumors outside of NSCLC with Maverick Therapeutics, Black Diamond Therapeutics and Harvard Medical School.
Industry Pricing - Conference Only (First Release) USD 1599.00
Industry Pricing - Conference Only (Second Release) USD 1699.00
Industry Pricing - Conference Only (Third Release) USD 1799.00
Industry Pricing - Conference Only (Fourth Release) USD 1899.00
Industry Pricing - Conference Only (Standard Rate) USD 1899.00
Speakers: Asif Khan, Medical Therapy Area Lead – EGFR & IO – Lung Franchise, AstraZeneca, Emmett V. Schmidt, Vice President, Clinical Research Lead, External Collaborations Oncology Early Development, Merck and Co, Mike Humphries, US Scientific Director- Lung Cancer, Takeda, Leigh Zawel, Chief Scientific Officer Cullinan Oncology Executive Partner, MPM Capital, Cecile Geuijen, Vice President Oncology - Cell Biology, Merus, Martha Neagu, Associate Medical Director, AbbVie, Eric Murphy, Co-Founder and Chief Scientific Officer, Kinnate Biopharma, Sylvie Vincent, Scientific Director, Takeda, Robert Doebele, Chief Scientific Officer, Rain Therapeutics, Patty Culp, Senior Director, Maverick Therapeutics, Chiara Ambrogio, Assistant Professor of Molecular Biology, University of Turin, Serban Ghiorghiu, Head of Clinical, Late Development Oncology R&D, AstraZeneca & European Commission’s Mission for Cancer, Board Member, Ralph Neumueller, Senior Director - Cancer Research, Boeringer Ingelheim, Tony Jarkowski, Development Lead, Bristol Myers- Squibb, Kelly Covello, Head of Medical Affairs, Mirati Therapeutics, Hani Gabra, Chief Medical Officer & Head of Clinical Development, BerGenBio AS, Shawn Leland, Founder & Chief Executive Officer, Elevation Oncology, Frederic Triebel, Chief Scientific Officer & Chief Medical Officer, Immutep, Rachel Humphrey, Chief Medical Officer, Black Diamond Therapeutics, Donald Johann, Associate Professor - Medicine & Bioinformatics, University of Arkansas for Medical Sciences/ ATD LLC, Harish Dave, Co-Founder & Chief Medical Officer, AUM Biosciences, Matt Lucas, Vice President – Chemistry, Black Diamond Therapeutics, Naveen Babbar, Global Biomarker and Diagnostic Lead, Oncology Solid Tumors (Vice President), Novartis, Lauren Leiman, Executive Director, Blood Profiling Atlas in Cancer, Fairooz Kabbinavar, Senior VP Clinical Development, Puma Biotechnology, Ryan B. Corcoran, Director, Gastrointestinal Cancer Center Program, Scientific Director Termeer Center for Targeted Therapy, Massachusetts General Hospital Cancer Center, Associate Professor of Medicine, Harvard Medical School, Partha M. Das, Medical Director and US Medical Affairs Lead, Oncology Diagnostics and Biomarker Strategy, Amgen